FMC RENALCARE CORP.

Fresenius Medical Care Advances U.S. Rollout of High-Volume Hemodiafiltration Following FDA Clearance

- Fresenius Medical Care received FDA 510(k) clearance for its enhanced 5008X CAREsystem, enabling broader U.S. commercialization of high-volume hemodiafiltration therapy. - The CONVINCE study demonstrated a 23% reduction in mortality rates for patients receiving high-volume hemodiafiltration compared to traditional high-flux hemodialysis. - The company will begin offering the therapy in selected Fresenius Kidney Care clinics throughout 2025, with full commercial launch planned for 2026. - The updated system includes Fresenius Clinical Data Exchange technology for improved workflow and reduced equipment clutter at chairside.